enGene (ENGN) Leerink Global Healthcare Conference 2026 summary

Program advancements and protocol changes

• Major protocol amendments included T1 re-resection, TA reinduction, and biopsy before study exit, aligning with standard of care and improving response rates holistically rather than from a single change.

• Biopsy-based assessment replaced visual impression, increasing consistency with standard practice and positively impacting efficacy rates.

• Post-amendment, patients are assessed at three and six months, with reinduction for non-responders at six months; only responders continue therapy.

• 23 patients in the post-amendment cohort achieved six-month complete response, with 12-month data expected in the second half of the year and an interim update planned for a medical conference in Q2.

• Focus remains on the pivotal cohort, which exceeded enrollment targets, while other cohorts are lower priority but ongoing.

Regulatory and data strategy

• Shifted primary endpoint from six-month CR to CR at any time to align with FDA guidance and competitive benchmarks.

• Post-amendment cohort (94 patients) now dominates the data package, with pre-amendment patients having minimal impact; ongoing discussions with FDA on statistical analysis plan.

• Safety database is robust with 125 patients, exceeding typical requirements and showing strong tolerability with low discontinuation rates.

• RMAT and CDRP designations facilitate early and frequent FDA engagement, supporting both clinical and manufacturing readiness.

Commercial positioning and strategy

• Product designed for ease of use in community urology practices, requiring no special equipment or staff, and can be administered by various healthcare providers.

• Non-viral gene therapy offers storage and handling advantages, with simple administration and minimal patient burden compared to competitors.

• Buy and bill model is attractive for urologists, with over 80% of patients seen in community settings; product fits well with practice economics and workflow.

• Pricing strategy remains flexible due to low cost of goods, with potential to maximize value as market evolves.

• Transitioning to commercial phase will shift expenses from clinical and CMC to G&A and commercial, with strong cash position into 2028 and potential approval expected in 2027.